AS OF MAY 07, 2019

Our Pipeline

Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry.

Expand All Collapse All

Medical Aesthetics

Pharmaceuticals

BOTOX

Skin Quality

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

BoNTE

Glabellar Lines

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

BOTOX

Platysma Prominence

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

BOTOX

Masseter Prominence

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

NivobotulinumtoxinA

Facial Lines

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

Devices

AAM SubQ Body Filler

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

ADM Subdermal Body Filler

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

CoolSculpting Cellulite

Non-Surgical Fat Reduction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

CoolSculpting Cryo RF

Non-Surgical Fat Reduction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Elastagen

Skin Quality

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Rejuvecross

Etched Lines Wrinkles

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Rejuvecross Volumize

Cheek Augmentation

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

AlloDerm Select

Non-Breast Applications

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Elastagen

Acne Scars

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Inspira Single Use Sizers

Breast Reconstruction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Rejuvecross Deep Wrinkles

Nasolabial Folds

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Strattice Contaminated Hernia

Soft Tissue Support

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

CoolTone™

Muscle Stimulation

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Juvéderm

Décolletage

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Juvéderm

Hands

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Juvéderm

Neck Lines

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Revolve ENVI 600

Adipose Tissue

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Artia

Breast Reconstruction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Artia EU Pre-Pec

Breast Reconstruction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

CoolSculpting COM-2

Non-Surgical Fat Reduction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

CoolSculpting COM-3

Non-Surgical Fat Reduction

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Microcell

Breast Augmentation

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Volbella

Filler for Tear Trough

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Voluma

Temple

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Voluma Global

Malar Augmentation

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Voluma XC

Filler for Chin

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Volux

Facial Volumes

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Injectable

Eye Care

Pharmaceuticals

Abicipar (DARPin®)

DME

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

AGN-151597

Retinitis Pigmentosa

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

Note Optogenetic Gene Therapy

Ocular Surface Insert

Bimatoprost Ring

Glaucoma

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule and Device

Delivery Mechanism Other

Ocular Surface Insert

Brimonidine DDS

Geographic Atrophy

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule and Device

Delivery Mechanism Injectable

Brimonidine DDS

Glaucoma Neuroprotection

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule and Device

Delivery Mechanism Injectable

Next Gen Gel

Dry Eye

Phase 1

Phase 2

Phase 3

Approved

Type Other

Delivery Mechanism Topical

Optive Super

Dry Eye

Phase 1

Phase 2

Phase 3

Approved

Type Other

Delivery Mechanism Topical

Abicipar (DARPin®)

AMD

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

Bimatoprost SR

Glaucoma

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule and Device

Delivery Mechanism Other or Injectable

Optive Fusion

MDPF

Phase 1

Phase 2

Phase 3

Approved

Type Other

Delivery Mechanism Topical

Optive Lite MDPF

Dry Eye

Phase 1

Phase 2

Phase 3

Approved

Type Other

Delivery Mechanism Topical

Presbysol

Presbyopia

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Topical

Refresh Mega-3 MDPF

Dry Eye

Phase 1

Phase 2

Phase 3

Approved

Type Other

Delivery Mechanism Topical

Devices

True Tear Element

Dry Eye

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Intranasal

XEN45

Angle Closure Glaucoma

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

XEN63

Open Angle Glaucoma

Concept

Feasibility

Development

Confirmation

Type Device

Delivery Mechanism Other

Central Nervous System

Pharmaceuticals

AGN-242071

Alzheimer’s Disease

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note M1 agonist

AGN-242626

Alzheimer’s Disease

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note M4 agonist

Cariprazine

Autism Spectrum Disorder

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

AGN-241751

MDD

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note NMDA part. co-agonist

Neurotoxin

MDD

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

Atogepant

Migraine Prevention

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note CGRP Receptor Antagonist

Cariprazine

Adjunctive MDD

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Capsule

Ubrogepant

Acute Treatment of Migraine

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note CGRP Receptor Antagonist

Gastroenterology

Pharmaceuticals

AGN-242266

NASH

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note FXR Agonist – 1st Gen

Microbiome Platform

Ulcerative Colitis

Phase 1

Phase 2

Phase 3

Approved

Type Other

Delivery Mechanism Oral

Brazikumab

Ulcerative Colitis

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

Brazikumab

Crohn’s Disease

Phase 1

Phase 2

Phase 3

Approved

Type Biologic

Delivery Mechanism Injectable

CVC + Tropifexor

NASH

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Linaclotide

IBS-D Pain

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Note Delayed Release

Cenicriviroc

NASH

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Oral

Relamorelin

Diabetic Gastroparesis

Phase 1

Phase 2

Phase 3

Approved

Type Small Molecule

Delivery Mechanism Injectable